Grundinformationen
- Standard-SMILES
N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)[O-].[Na+]- InChIKey
SBXXSUDPJJJJLC-YDALLXLXSA-M- Summenformel
- C15H11I3NNaO4
- Durchschnittliche Molmasse
- 672,95 g/mol
- Monoisotopische Masse
- 672,77199611
Überblick
Liothyronine sodium is the sodium salt of liothyronine. Thought to be more active than levothyroxine and with a rapid (few hours) onset and short duration of action, liothyronine sodium is used in the treatment of hypothyroidism, particularly in cases of hypothyroid coma. It contains a 3,3',5-triiodo-L-thyroninate.
Namen und Bezeichner
- Bevorzugter Name
- Liothyronine Sodium
- IUPAC
- sodium (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
Namen und Synonyme
LIOTHYRONINE SODIUM55-06-13,3',5-Triiodo-L-thyronine sodium saltTriostatBasoprocinIbiothyronT3 sodium saltCynomelL-Triiodothyronine sodium saltCytobinLiothyronine sodium salt3,3',5-Triiodo-L-thyronine sodium
Weitere Namen anzeigen
Liotrix (t3)Triiodothyronine Sodium Salt3,3',5-Triiodothyronine sodium saltLyothyroninL-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, monosodium saltGCA9VV7D2NRathyronine sodium, (s)-CHEBI:6484
Datenbank-Bezeichner
- CAS
55-06-1- PubChem CID
- 23666110
- DTXSID
DTXSID8047505- ChEMBL
CHEMBL1201119- ChEBI
CHEBI:6484- UNII
- GCA9VV7D2N
- EC Number
- 200-223-5
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 95,6 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 5
- Frei drehbare Bindungen
- 5
- Schwere Atome
- 24
- Formalladung
- 0
- Komplexität
- 408
Experimentelle und physikochemische Eigenschaften
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Animal DrugsActive Ingredients (Liothyronine Sodium) -> FDA Greenbook
Collision Cross Section205.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
This chemical does not meet GHS hazard criteria for 40% (2 of 5) of reports.
Warning
H302 (40%): Harmful if swallowed [Warning Acute toxicity, oral]
P260, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P337+P317, P362+P364, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 5 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Other Safety InformationIMAP assessments - L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, monosodium salt: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (40%)
Toxikologische Informationen
Exposure Routes95% in 4 hours
Toxicity Summary
The hormones, T<sub>4</sub> and T<sub>3</sub>, are tyrosine-based hormones produced by the thyroid gland. Iodine is an important component in their synthesis. The major form of thyroid hormone in the blood is thyroxine (T<sub>4</sub>). This is converted to the more active liothyronine form by deiodinases in peripheral tissues. Liothyronine acts on the body to increase the basal metabolic rate, affect protein synthesis and increase the body's sensitivity to catecholamines (such as adrenaline). The thyroid hormones are essential to proper development and differentiation of all cells of the human body. To various extents T<sub>4</sub> and T<sub>3</sub> regulate protein, fat and carbohydrate metabolism. Their most pronounced effect is on how human cells use energetic compounds. The thyroid hormone derivatives bind to the thyroid hormone receptors initially to initiate their downstream effects.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Liothyronine sodium
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
Chemie und Industrie
Pharmakologische Informationen
ATC Code
H - Systemic hormonal preparations, excl. sex hormones and insulins
QH - Systemic hormonal preparations, excl. sex hormones and insulin
Metabolism/MetabolitesHalf Life: 2.5 days
FDA Pharmacological Classification
LIOTHYRONINE SODIUM
l-Triiodothyronine [EPC]; Triiodothyronine [CS]
Verwendung und Herstellung
UsesUsed as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyrodism during the recovery phase of subacute thyroiditis.
Use ClassificationAnimal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients
Zugehörige Reaktionen
2
Verknüpfte Notizen
Wird geladen…